This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(0)
- Annex to CHMP highlights(0)
- Annual Report(0)
- Application withdrawal assessment report(0)
- Committee meeting report(0)
- COVID-19 vaccine safety update(0)
- Direct healthcare professional communication(0)
- EPAR - All authorised presentations(0)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(0)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(0)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(0)
- EPAR - Overview(0)
- EPAR - Paediatric investigation plan compliance statement(0)
- EPAR - Procedural steps taken and scientific information after authorisation(0)
- EPAR - Procedural steps taken before authorisation(0)
- EPAR - Product Information(0)
- EPAR - Public assessment report(0)
- EPAR - Risk-management-plan summary(0)
- EPAR - Scientific conclusion(0)
- EPAR - Scientific Discussion(0)
- EPAR - Scientific Discussion - Variation(0)
- EPAR - Steps taken after authorisation when a cutoff date has been used(0)
- Herbal - Call for data(0)
- Herbal - Herbal monograph(0)
- Herbal - HMPC assessment report(0)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(0)
- Herbal - Overview of comments received during consultation(0)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(0)
- Herbal – European Union list entry(0)
- Leaflet(0)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(0)
- Medicines under additional monitoring(0)
- Minutes(0)
- Newsletter(0)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(0)
- Orphan review(0)
- Other(0)
- Overview of comments(0)
- Parallel distribution(0)
- Periodic safety update single assessment(0)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(0)
- PIP - Paediatric-investigation-plan summary(0)
- PIP decision(0)
- Position statement(0)
- PRAC recommendation on signal(0)
- Presentation(0)
- Press Release(0)
- Procurement(0)
- Public Statement(0)
- Recommendation on medication errors(0)
- Recruitment(0)
- Referrals document(0)
- Regulatory and procedural guideline(0)
- Report(0)
- Scientific guideline(0)
- Standard Operating Procedure - SOP(0)
- Summary of opinion(0)
- Summary of opinion - Initial authorisation(0)
- Supply shortage(0)
- Template or form(0)
- Withdrawal letter(0)
- Work Instruction - WIN(0)
- Work programme(0)
- Advanced therapies(398)
- Antimicrobial resistance(46)
- Biologicals(24)
- Biosimilars(151)
- Brexit(30)
- Careers(3)
- Clinical trials(182)
- Compassionate use(4)
- Compliance and inspections(105)
- Corporate(47)
- COVID-19(466)
- Data on medicines(166)
- Early access(25)
- Fees(12)
- Generic and hybrid medicines(398)
- Governance(91)
- Innovation(283)
- Maximum residue limit(17)
- Medication error(6)
- Medicines(7751)
- Medicines for use outside the EU(29)
- Medicine shortages(120)
- Mpox(17)
- Paediatrics(3078)
- Parallel distribution(6)
- Pharmacovigilance(2914)
- Procurement(9)
- Product information(61)
- Quality of medicines(84)
- Rare diseases(3275)
- Referrals(373)
- Regulatory and procedural guidance(551)
- Research and development(228)
- Scientific advice(37)
- Scientific guidelines(1013)
- SME(62)
- Vaccines(381)
- Veterinary limited markets(15)
Search results (24241)
Online
European Medicines Agency, Amsterdam, the Netherlands
Live broadcast
Start date:
26 June 2024, 09:00 (CEST)
End date:
26 June 2024, 13:30 (CEST)
EventCorporate
human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)
Papillomavirus Infections
Uterine Cervical Dysplasia
Immunization
Date of authorisation:
Revision:
39
Last updated:
MedicineHumanAuthorised
sodium thiosulfate
Ear Diseases
Ototoxicity
Date of authorisation:
Revision:
3
Last updated:
MedicineHumanAuthorised
miglustat
Glycogen Storage Disease Type II
Date of authorisation:
Revision:
2
Last updated:
MedicineHumanAuthorised
COVID-19 mRNA vaccine
tozinameran
riltozinameran and tozinameran
famtozinameran and tozinameran
raxtozinameran
COVID-19 virus infection
Date of authorisation:
Revision:
47
Last updated:
MedicineHumanAuthorised
European Medicines Agency, Amsterdam, the Netherlands
Start date:
8 April 2024
End date:
11 April 2024
EventHumanPharmacovigilance
European Medicines Agency, Amsterdam, the Netherlands
Start date:
18 March 2024
End date:
21 March 2024
EventHumanMedicines
This meeting is organised is organised in the context of the EMA annual bilateral meetings with industry stakeholder organisations.
European Medicines Agency, Amsterdam, the Netherlands
Start date:
2 July 2024
End date:
2 July 2024
EventHumanMedicines
Online
European Medicines Agency, Amsterdam, the Netherlands
Start date:
15 April 2024
End date:
16 April 2024
EventHumanMedicine shortages
Ramipril
Procedure number:
PSUSA/00002607/202308
Regulatory outcome:
Maintenance
Last updated:
PSUSAHuman